These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

730 related articles for article (PubMed ID: 33455075)

  • 1. Inhibition of galectin-3 augments the antitumor efficacy of PD-L1 blockade in non-small-cell lung cancer.
    Zhang H; Liu P; Zhang Y; Han L; Hu Z; Cai Z; Cai J
    FEBS Open Bio; 2021 Mar; 11(3):911-920. PubMed ID: 33455075
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Small Molecule Antagonist of PD-1/PD-L1 Interactions Acts as an Immune Checkpoint Inhibitor for NSCLC and Melanoma Immunotherapy.
    Wang Y; Gu T; Tian X; Li W; Zhao R; Yang W; Gao Q; Li T; Shim JH; Zhang C; Liu K; Lee MH
    Front Immunol; 2021; 12():654463. PubMed ID: 34054817
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
    Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
    Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
    [No Abstract]   [Full Text] [Related]  

  • 4. Niclosamide, an antihelmintic drug, enhances efficacy of PD-1/PD-L1 immune checkpoint blockade in non-small cell lung cancer.
    Luo F; Luo M; Rong QX; Zhang H; Chen Z; Wang F; Zhao HY; Fu LW
    J Immunother Cancer; 2019 Sep; 7(1):245. PubMed ID: 31511071
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An Orally Active Galectin-3 Antagonist Inhibits Lung Adenocarcinoma Growth and Augments Response to PD-L1 Blockade.
    Vuong L; Kouverianou E; Rooney CM; McHugh BJ; Howie SEM; Gregory CD; Forbes SJ; Henderson NC; Zetterberg FR; Nilsson UJ; Leffler H; Ford P; Pedersen A; Gravelle L; Tantawi S; Schambye H; Sethi T; MacKinnon AC
    Cancer Res; 2019 Apr; 79(7):1480-1492. PubMed ID: 30674531
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cisplatin increases PD-L1 expression and optimizes immune check-point blockade in non-small cell lung cancer.
    Fournel L; Wu Z; Stadler N; Damotte D; Lococo F; Boulle G; Ségal-Bendirdjian E; Bobbio A; Icard P; Trédaniel J; Alifano M; Forgez P
    Cancer Lett; 2019 Nov; 464():5-14. PubMed ID: 31404614
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bu Fei Decoction attenuates the tumor associated macrophage stimulated proliferation, migration, invasion and immunosuppression of non-small cell lung cancer, partially via IL-10 and PD-L1 regulation.
    Pang L; Han S; Jiao Y; Jiang S; He X; Li P
    Int J Oncol; 2017 Jul; 51(1):25-38. PubMed ID: 28534943
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Apatinib triggers autophagic and apoptotic cell death via VEGFR2/STAT3/PD-L1 and ROS/Nrf2/p62 signaling in lung cancer.
    Xie C; Zhou X; Liang C; Li X; Ge M; Chen Y; Yin J; Zhu J; Zhong C
    J Exp Clin Cancer Res; 2021 Aug; 40(1):266. PubMed ID: 34429133
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An increase in BAG-1 by PD-L1 confers resistance to tyrosine kinase inhibitor in non-small cell lung cancer via persistent activation of ERK signalling.
    Lin PL; Wu TC; Wu DW; Wang L; Chen CY; Lee H
    Eur J Cancer; 2017 Nov; 85():95-105. PubMed ID: 28892778
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Upregulation of programmed cell death ligand 1 promotes resistance response in non-small-cell lung cancer patients treated with neo-adjuvant chemotherapy.
    Zhang P; Ma Y; Lv C; Huang M; Li M; Dong B; Liu X; An G; Zhang W; Zhang J; Zhang L; Zhang S; Yang Y
    Cancer Sci; 2016 Nov; 107(11):1563-1571. PubMed ID: 27581532
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CPI-203 improves the efficacy of anti-PD-1 therapy by inhibiting the induced PD-L1 overexpression in liver cancer.
    Niu X; Wang W; Liang T; Li S; Yang C; Xu X; Li L; Liu S
    Cancer Sci; 2022 Jan; 113(1):28-40. PubMed ID: 34727389
    [TBL] [Abstract][Full Text] [Related]  

  • 12. N
    Liu Z; Wang T; She Y; Wu K; Gu S; Li L; Dong C; Chen C; Zhou Y
    Mol Cancer; 2021 Aug; 20(1):105. PubMed ID: 34416901
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Down-regulation of RCC1 sensitizes immunotherapy by up-regulating PD-L1 via p27
    Zeng X; Zhong M; Yang Y; Wang Z; Zhu Y
    J Cell Mol Med; 2021 Apr; 25(8):4136-4147. PubMed ID: 33630417
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Continuous targeted kinase inhibitors treatment induces upregulation of PD-L1 in resistant NSCLC.
    Jiang L; Guo F; Liu X; Li X; Qin Q; Shu P; Li Y; Wang Y
    Sci Rep; 2019 Mar; 9(1):3705. PubMed ID: 30842489
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Programmed death (PD)-1/PD-ligand 1 blockade mediates antiangiogenic effects by tumor-derived CXCL10/11 as a potential predictive biomarker.
    Mitsuhashi A; Kondoh K; Horikawa K; Koyama K; Nguyen NT; Afroj T; Yoneda H; Otsuka K; Ogino H; Nokihara H; Shinohara T; Nishioka Y
    Cancer Sci; 2021 Dec; 112(12):4853-4866. PubMed ID: 34628702
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Galectin-9 blockade synergizes with ATM inhibition to induce potent anti-tumor immunity.
    Zheng S; Song J; Linghu D; Yang R; Liu B; Xue Z; Chen Q; Liu C; Zhong D; Hung MC; Sun L
    Int J Biol Sci; 2023; 19(3):981-993. PubMed ID: 36778120
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Luteolin and its derivative apigenin suppress the inducible PD-L1 expression to improve anti-tumor immunity in KRAS-mutant lung cancer.
    Jiang ZB; Wang WJ; Xu C; Xie YJ; Wang XR; Zhang YZ; Huang JM; Huang M; Xie C; Liu P; Fan XX; Ma YP; Yan PY; Liu L; Yao XJ; Wu QB; Lai-Han Leung E
    Cancer Lett; 2021 Sep; 515():36-48. PubMed ID: 34052328
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Water extract of sporoderm-broken spores of Ganoderma lucidum enhanced pd-l1 antibody efficiency through downregulation and relieved complications of pd-l1 monoclonal antibody.
    He J; Zhang W; Di T; Meng J; Qi Y; Li G; Zhang Y; Su H; Yan W
    Biomed Pharmacother; 2020 Nov; 131():110541. PubMed ID: 33152901
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Methylseleninic acid overcomes programmed death-ligand 1-mediated resistance of prostate cancer and lung cancer.
    Hu W; Ma Y; Zhao C; Yin S; Hu H
    Mol Carcinog; 2021 Nov; 60(11):746-757. PubMed ID: 34411338
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sensitizing tumors to anti-PD-1 therapy by promoting NK and CD8+ T cells via pharmacological activation of FOXO3.
    Chung YM; Khan PP; Wang H; Tsai WB; Qiao Y; Yu B; Larrick JW; Hu MC
    J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34887262
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 37.